From a Positive Cervical Screening Result to Completed Follow-Up: A Proposed Event-Level Measurement Framework for Saudi and Gulf Services

Abstract

Background: The benefit of human papillomavirus (HPV) screening depends on appropriate care after a positive result. Clinical pathways differ by genotype, cytology, prior history, specimen type and programme capacity. A recorded positive test, a released portal message and a completed diagnostic or surveillance episode are not equivalent events. Methods: We conducted a targeted, non-systematic narrative review of PubMed-indexed studies, SciSpace discovery leads, and original WHO and ASCCP guidance available through 28 September 2026. We examined clinical branching, follow-up indicators, intervention studies, computable guidelines and Gulf evidence. Synthesis: WHO's 2023 monitoring framework and 2026 implementation and genotyping guidance already define important indicators and capacity concepts. Earlier programme and research models also describe care stages. Yet the operational choices required to derive risk-specific denominators, distinguish patient receipt from message release, join referral and procedure records, and classify unknown outcomes across providers remain consequential. Proposal: We specify an unvalidated, locally governed event-level framework: a versioned clinical-action rule; one first-valid-positive index episode per person in a versioned reporting cohort; source-timestamped evidence of ownership, patient acknowledgment and performed action; and explicit superseding, competing and unknown states. A local service-opportunity rate and a broader linked-network patient-pathway rate use separately defined matching denominators and numerators. Each rate is paired with its index count and excluded or unresolved states; invalidated or duplicate index results trigger auditable cohort restatement. WHO programme-capacity classification is kept separate from local process measures; no single patient deadline is applied to every positive test. Conclusion: This is a methods proposal, not a validated Saudi pathway, clinical guideline or empirical estimate. Local clinicians, patients and data stewards must test feasibility, accuracy, equity and safety before adoption.

Keywords

• cervical cancer screening
• human papillomavirus
• abnormal result
• diagnostic follow-up
• quality measurement
• Saudi Arabia
• Gulf Cooperation Council